ישראל - עברית - Ministry of Health

unipharm ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 10 mg - pravastatin

ישראל - עברית - Ministry of Health

astra zeneca (israel) ltd - zolmitriptan - טבליות מתמוססות בפה - zolmitriptan 2.5 mg - zolmitriptan - zolmitriptan - acute treatment of migraine with or without aura.

ישראל - עברית - Ministry of Health

teva medical marketing ltd. - sodium chloride - תמיסה לאינפוזיה - sodium chloride 0.9 %w/v - sodium chloride - sodium chloride - treatment of isotonic extracellular dehydration. treatment of sodium depletion. vehicle or diluent of compatible drugs for parenteral administration.

ישראל - עברית - Ministry of Health

teva medical marketing ltd. - sodium chloride - תמיסה לאינפוזיה - sodium chloride 0.9 %w/v - sodium chloride - sodium chloride - treatment of isotonic extracellular dehydration. treatment of sodium depletion. vehicle or diluent of compatible drugs for parenteral administration.

ישראל - עברית - Ministry of Health

sanofi israel ltd - metronidazole - טבליות מצופות פילם - metronidazole 250 mg - metronidazole - metronidazole - trichomonias, acute intestinal amebiasis. infections due to anaerobic bacteria.

ישראל - עברית - Ministry of Health

abic marketing ltd, israel - apomorphine hydrochloride - תמיסה להזרקה\אינפוזיה - apomorphine hydrochloride 10 mg/ml - apomorphine - apomorphine - the treatment of disabling motor fluctuations ("on-off" phenomena) in patients with parkinson's disease which persist despite individually titrated treatment with levodopa (with a peripheral decarboxylase inhibitor) and/or other dopamine agonists.

ישראל - עברית - Ministry of Health

teva israel ltd - apomorphine hydrochloride - תמיסה להזרקה - apomorphine hydrochloride 10 mg/ml - apomorphine - apomorphine - the treatment of disabling motor fluctuations ( "on-off" phenomena) in patients with parkinson's disease which persist despite individually titrated treatment with levodopa ( with a peripheral decarboxylase inhibitor ) and/or other dopamine agonists.

ישראל - עברית - Ministry of Health

astrazeneca (israel) ltd - budesonide micronized; formoterol fumarate - אבקה לשאיפה - budesonide micronized 80 mcg/dose; formoterol fumarate 4.5 mcg/dose - formoterol and budesonide - formoterol and other drugs for obstructive airway diseases - symbicort turbuhaler is indicated in the regular treatment of asthma where use of a combination (inhaled corticosteroid and long acting beta-agonist) is appropriate: - patients not adequaterly controlled with inhaled corticosteroids and " as needed" inhaled short acting beta2- agonists. - or patients already adequately controlled on both inhaled corticosteroids and long acting beta2- agonists. note: symbicort turbuhaler 80/4.5 mcg/dose is not appropriate in patients with severe asthma.

ישראל - עברית - Ministry of Health

astrazeneca (israel) ltd - budesonide micronized; formoterol fumarate - אבקה לשאיפה - budesonide micronized 160 mcg/dose; formoterol fumarate 4.5 mcg/dose - formoterol and budesonide - formoterol and other drugs for obstructive airway diseases - asthma symbicort turbuhaler is indicated in the regular treatment of asthma in adults and adolescents age 12 years and above where use of a combination (inhaled corticosteroid and long acting beta-agonist) is appropriate: - patients not adequately controlled with inhaled corticosteroids and " as needed" inhaled short acting beta2- agonists. or - patients already adequately controlled on both inhaled corticosteroids and long acting beta2- agonists. copd symptomatic treatment of patients with severe copd (fev1 < 50 % predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular therapy with long-acting bronchodilators.

ישראל - עברית - Ministry of Health

astrazeneca (israel) ltd - budesonide micronized; formoterol fumarate - אבקה לשאיפה - budesonide micronized 320 mcg/dose; formoterol fumarate 9 mcg/dose - formoterol and budesonide - formoterol and other drugs for obstructive airway diseases - symbicort turbuhaler is indicated in the regular treatment of asthma in adults and adolescents (over the age of 12 years) where use of a combination (inhaled corticosteroid and long acting beta-agonist) is appropriate: - patients not adequaterly controlled with inhaled corticosteroids and " as needed" inhaled short acting beta2- agonists. - or patients already adequately controlled on both inhaled corticosteroids and long acting beta2- agonists. copd symptomatic treatment of patients with severe copd (fev1 < 50 % predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular therapy with long-acting bronchodilators.